This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Merck & Co., Inc.
Drug Names(s): Lisinopril and hydrochlorothiazide
Description: Prinzide is a combination of the angiotensin converting enzyme inhibitor (ACEI) lisinopril and the diuretic hydrochlorothiazide. ACEIs work by preventing angiotensin I from converting into a more potent form that increases salt and water retention in the body and constricts blood vessels, though other mechanisms, such as inhibiting the degradation of the vasodilator bradykinin, may be involved in their longer term effects. Hydrochlorothiazide is a diuretic: it acts at the distal renal tubules of the kidney to increase salt and hence urine excretion, thereby reducing the volume of fluids in the circulation.
Pink Sheet February Supplemental Approvals
Pink Sheet June Supplemental Approvals
Pink Sheet August Supplemental Approvals
Additional information available to subscribers only: